CAMP4 Therapeutics financials
$3.91+1.56%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $3.5M | $652.0K |
| Gross profit | $3.5M | $652.0K |
| Gross margin | 100.0% | 100.0% |
| Operating income | -$52.6M | -$53.1M |
| Net income | -$80.4M | -$51.8M |
| Net margin | −2298.5% | −7943.4% |
| Diluted EPS | $-2.65 | $-11.04 |
| EBITDA | -$50.4M | -$51.4M |
| Operating cash flow | -$29.6M | -$45.6M |
| Free cash flow | -$29.8M | -$46.0M |
| Diluted shares | 30.4M | 4.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $109.5M | $64.0M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 |
| Total assets | $117.8M | $78.3M |
| Total liabilities | $70.1M | $15.2M |
| Shareholders' equity | $47.7M | $63.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology